Neurology
Partner With Us
Advertisement
Conexiant chevron_right Neurology chevron_right Early RNAi Therapeutic Treatment May Improve Survival in hATTR-PN
From the Journals

Early RNAi Therapeutic Treatment May Improve Survival in hATTR-PN

"In a disease characterized by unrelenting decline, the results depict the long-term clinical stability afforded by TTR reduction and the long-term safety of patisiran treatment."

Conexiant
article Full Article subject Summary summarize Notecard
  1. Early treatment with patisiran for hereditary transthyretin amyloidosis with polyneuropathy led to better clinical stability and survival.
  2. Investigaors enrolled 211 patients across 19 countries into a 5-year global open-label extension study, with 138 completing the global extension.
  3. Patients receiving patisiran exhibited a lower mortality rate.
  4. Multivariate analysis identified familial amyloid polyneuropathy stage and prior treatment as independent predictors of survival.
  5. Findings support the long-term safety and efficacy of RNA interference therapeutics in chronic disease management.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.